Abstract
Original language | English |
---|---|
Pages (from-to) | 1914-1923 |
Number of pages | 10 |
Journal | European Journal of Surgical Oncology |
Volume | 42 |
Issue number | 12 |
DOIs | |
Publication status | Published - 2016 |
Keywords
- Basal cell carcinoma
- Breast cancer
- Cutaneous metastases
- Electrochemotherapy
- Melanoma
- Squamous cell carcinoma
Fingerprint
Dive into the research topics of 'Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors. / Campana, L.G.; Testori, A.; Curatolo, Paolo; Quaglino, P.; Mocellin, S.; Framarini, Massimo; Borgognoni, L.; Ascierto, P.A.; Mozzillo, N.; Guida, M.; Bucher, S.; Rotunno, R.; Marenco, Federica; De Salvo, G.L.; De Paoli, A.; Rossi, C.R.; Bonadies, A.
In: European Journal of Surgical Oncology, Vol. 42, No. 12, 2016, p. 1914-1923.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors
AU - Campana, L.G.
AU - Testori, A.
AU - Curatolo, Paolo
AU - Quaglino, P.
AU - Mocellin, S.
AU - Framarini, Massimo
AU - Borgognoni, L.
AU - Ascierto, P.A.
AU - Mozzillo, N.
AU - Guida, M.
AU - Bucher, S.
AU - Rotunno, R.
AU - Marenco, Federica
AU - De Salvo, G.L.
AU - De Paoli, A.
AU - Rossi, C.R.
AU - Bonadies, A.
N1 - Cited By :1 Export Date: 28 March 2017 CODEN: EJSOE Correspondence Address: Campana, L.G.; Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCSItaly; email: luca.campana@ioveneto.it References: Alcaraz, I., Cerroni, L., Rutten, A., Kutzner, H., Requena, L., Cutaneous metastases from internal malignancies: a clinicopathologic and immunohistochemical review (2012) Am J Dermatopathol, 34, pp. 347-393; Savoia, P., Fava, P., Nardo, T., Osella-Abate, S., Quaglino, P., Bernengo, M.G., Skin metastases of malignant melanoma: a clinical and prognostic survey (2009) Melanoma Res, 19, pp. 321-326; Rolz-Cruz, G., Kim, C.C., Tumor invasion of the skin (2008) Dermatol Clin, 26, pp. 89-102 viii; Meaume, S., Fromantin, I., Teot, L., Neoplastic wounds and degenerescence (2013) J Tissue Viability, 22, pp. 122-130; Spratt, D.E., Gordon Spratt, E.A., Wu, S., Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis (2014) J Clin Oncol, 32, pp. 3144-3155; Agarwala, S.S., Intralesional therapy for advanced melanoma: promise and limitation (2015) Current Opin Oncol, 27, pp. 151-156; Andtbacka, R.H., Kaufman, H.L., Collichio, F., Talimogene laherparepvec improves durable response rate in patients with advanced melanoma (2015) J Clin Oncol, 33, pp. 2780-2788; Mir, L.M., Orlowski, S., Belehradek, J., Jr., Paoletti, C., Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses (1991) Eur J Cancer, 27, pp. 68-72; Belehradek, M., Domenge, C., Luboinski, B., Orlowski, S., Belehradek, J., Jr., Mir, L.M., Electrochemotherapy, a new antitumor treatment. First clinical phase I–II trial (1993) Cancer, 72, pp. 3694-3700; Marty, M., Sersa, G., Garbay, J.R., Electrochemotherapy – an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study (2006) Eur J Cancer Suppl, 4, pp. 3-13; Orlowski, S., Belehradek, J., Jr., Paoletti, C., Mir, L.M., Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs (1988) Biochem Pharmacol, 37, pp. 4727-4733; Sersa, G., Cemazar, M., Miklavcic, D., Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice (1995) Cancer Res, 55, pp. 3450-3455; Sersa, G., Miklavcic, D., Cemazar, M., Rudolf, Z., Pucihar, G., Snoj, M., Electrochemotherapy in treatment of tumours (2008) Eur J Surg Oncol, 34, pp. 232-240; Heller, R., Jaroszeski, M.J., Glass, L.F., Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy (1996) Cancer, 77, pp. 964-971; Heller, R., Jaroszeski, M.J., Reintgen, D.S., Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin (1998) Cancer, 83, pp. 148-157; Sersa, G., Stabuc, B., Cemazar, M., Miklavcic, D., Rudolf, Z., Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients (2000) Clin Cancer Res, 6, pp. 863-867; Mir, L.M., Gehl, J., Sersa, G., Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the Cliniporator (TM) by means of invasive or non-invasive electrodes (2006) Eur J Cancer Suppl, 4, pp. 14-25; Mali, B., Jarm, T., Snoj, M., Sersa, G., Miklavcic, D., Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis (2013) Eur J Surg Oncol, 39, pp. 4-16; Campana, L.G., Clover, A.J., Valpione, S., Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review (2016) Radiol Oncol, 50, pp. 1-13; Campana, L.G., Valpione, S., Falci, C., The activity and safety of electrochemotherapy in persistent chest wall recurrence from breast cancer after mastectomy: a phase-II study (2012) Breast Cancer Res Treat, 134, pp. 1169-1178; Matthiessen, L.W., Johannesen, H.H., Hendel, H.W., Moss, T., Kamby, C., Gehl, J., Electrochemotherapy for large cutaneous recurrence of breast cancer: a phase II clinical trial (2012) Acta Oncol, 51, pp. 713-721; Campana, L.G., Mali, B., Sersa, G., Electrochemotherapy in non-melanoma head and neck cancers: a retrospective analysis of the treated cases (2014) Br J Oral Maxillofac Surg, 52, pp. 957-964; Therasse, P., Arbuck, S.G., Eisenhauer, E.A., New guidelines to evaluate the response to treatment in solid tumors (2000) J Natl Cancer Inst, 92, pp. 205-216; Campana, L.G., Mocellin, S., Basso, M., Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients (2009) Ann Surg Oncol, 16, pp. 191-199; Campana, L.G., Valpione, S., Mocellin, S., Electrochemotherapy for disseminated superficial metastases from malignant melanoma (2012) Br J Surg, 99, pp. 821-830; Quaglino, P., Mortera, C., Osella-Abate, S., Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases (2008) Ann Surg Oncol, 15, pp. 2215-2222; Jarm, T., Cemazar, M., Miklavcic, D., Sersa, G., Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases (2010) Expert Rev Anticancer Ther, 10, pp. 729-746; Quaglino, P., Matthiessen, L.W., Curatolo, P., Predicting patients at risk for pain associated with electrochemotherapy (2015) Acta Oncol, 54, pp. 298-306; Campana, L.G., Bianchi, G., Mocellin, S., Electrochemotherapy treatment of locally advanced and metastatic soft tissue sarcomas: results of a non-comparative phase II study (2014) World J Surg, 38, pp. 813-822; Kreuter, A., van Eijk, T., Lehmann, P., Electrochemotherapy in advanced skin tumors and cutaneous metastases – a retrospective multicenter analysis (2015) J Dtsch Dermatol Ges, 13, pp. 308-315; Cabula, C., Campana, L.G., Grilz, G., Electrochemotherapy in the treatment of cutaneous metastases from breast Cancer: a multicenter cohort analysis (2015) Ann Surg Oncol, 22, pp. 442-450; Matthiessen, L.W., Chalmers, R.L., Sainsbury, D.C., Management of cutaneous metastases using electrochemotherapy (2011) Acta Oncol, 50, pp. 621-629; Curatolo, P., Quaglino, P., Marenco, F., Electrochemotherapy in the treatment of Kaposi sarcoma cutaneous lesions: a two-center prospective phase II trial (2012) Ann Surg Oncol, 19, pp. 192-198; Mali, B., Miklavcic, D., Campana, L.G., Tumor size and effectiveness of electrochemotherapy (2013) Radiol Oncol, 47, pp. 32-41; Gerlini, G., Di Gennaro, P., Borgognoni, L., Enhancing anti-melanoma immunity by electrochemotherapy and in vivo dendritic-cell activation (2012) Oncoimmunology, 1, pp. 1655-1657; Mozzillo, N., Simeone, E., Benedetto, L., Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy (2015) Oncoimmunology, 4, p. e1008842
PY - 2016
Y1 - 2016
N2 - Background Cutaneous metastases represent a therapeutic challenge. An increasing body of experience suggests that electrochemotherapy (ECT) provides effective tumor control, although its evidence basis should be strengthened. Methods This prospective, multicenter, observational study enrolled patients with superficial metastases, who underwent ECT at 10 centers between 2008 and 2013. Outcomes included adherence to European Standard Operating Procedures of ECT (ESOPE), tumor response, local progression-free survival (LPFS), toxicity and patient-reported outcomes (PROs, EORTC QLQ-C30 plus an 8-item questionnaire). Results We enrolled 376 eligible patients. Tumor histotype distribution was as follows: melanoma, 56%; squamous cell carcinoma, 11%; Kaposi sarcoma, 11%; breast carcinoma, 8%; basal cell carcinoma, 6%; soft tissue sarcomas, 3%; others, 5%. We registered 1304 target tumors (median size 1 cm). Treatment adhered to ESOPE in 88% of patients as to the route of drug administration, and in 70% as to electrode application. The procedure was mainly performed under sedation (64.6%) and by using intravenous chemotherapy (93.4%). Tumor response rate at 60 days was 88% (complete, 50%). Small tumor size predicted complete response achievement (OR 2.24, p = 0.003), higher LPFS (HR 0.68, p = 0.004) and improved PROs (Global Health Status, p
AB - Background Cutaneous metastases represent a therapeutic challenge. An increasing body of experience suggests that electrochemotherapy (ECT) provides effective tumor control, although its evidence basis should be strengthened. Methods This prospective, multicenter, observational study enrolled patients with superficial metastases, who underwent ECT at 10 centers between 2008 and 2013. Outcomes included adherence to European Standard Operating Procedures of ECT (ESOPE), tumor response, local progression-free survival (LPFS), toxicity and patient-reported outcomes (PROs, EORTC QLQ-C30 plus an 8-item questionnaire). Results We enrolled 376 eligible patients. Tumor histotype distribution was as follows: melanoma, 56%; squamous cell carcinoma, 11%; Kaposi sarcoma, 11%; breast carcinoma, 8%; basal cell carcinoma, 6%; soft tissue sarcomas, 3%; others, 5%. We registered 1304 target tumors (median size 1 cm). Treatment adhered to ESOPE in 88% of patients as to the route of drug administration, and in 70% as to electrode application. The procedure was mainly performed under sedation (64.6%) and by using intravenous chemotherapy (93.4%). Tumor response rate at 60 days was 88% (complete, 50%). Small tumor size predicted complete response achievement (OR 2.24, p = 0.003), higher LPFS (HR 0.68, p = 0.004) and improved PROs (Global Health Status, p
KW - Basal cell carcinoma
KW - Breast cancer
KW - Cutaneous metastases
KW - Electrochemotherapy
KW - Melanoma
KW - Squamous cell carcinoma
U2 - 10.1016/j.ejso.2016.06.399
DO - 10.1016/j.ejso.2016.06.399
M3 - Article
VL - 42
SP - 1914
EP - 1923
JO - European Journal of Surgical Oncology
JF - European Journal of Surgical Oncology
SN - 0748-7983
IS - 12
ER -